



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

LY2119620

Cat. No.:	HY-15885
CAS No.:	886047-22-9
Molecular Formula:	C ₁₉ H ₂₄ ClN ₅ O ₃ S
Molecular Weight:	437.94
Target:	mAChR
Pathway:	GPCR/G Protein; Neuronal Signaling
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year



SOLVENT & SOLUBILITY

In Vitro	DMSO : 67.5 mg/mL (154.13 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		1 mM		2.2834 mL	11.4171 mL	22.8342 mL
		5 mM		0.4567 mL	2.2834 mL	4.5668 mL
		10 mM		0.2283 mL	1.1417 mL	2.2834 mL
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (5.71 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (5.71 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	LY2119620 is a high-affinity muscarinic M ₂ /M ₄ receptor agonist.
IC ₅₀ & Target	M ₂ /M ₄ receptor ^[1]
In Vitro	LY2119620 shows a modest allosteric agonism of 23.2±2.18% and 16.8±5.01% at the M₂ and M₄ receptors, respectively. Minimal allosteric agonism (<20%) is observed for LY2119620 at the M₁, M₃, and M₅ receptors. The variable K_B of LY2119620 for the allosteric binding site on the unoccupied receptor is found to be consistently about 1.9 to 3.4 μM. Results show a B_{max} increase at the M₂ receptor from 793±1.95 fmol/mg to 2850±162 fmol/mg upon addition of 10 μM LY2119620, and about a 5-fold increase in B_{max} at the M₄ receptor, 284±18.3 fmol/mg to 1340±42.2 fmol/mg^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Kinase Assay ^[1]

[³H]LY2119620 equilibrium binding is achieved by incubating 15 µg membranes, orthosteric ligand (100 µM), and various concentrations of [³H]LY2119620 (0.2 to 60 nM) for 1 hour at 25°C. The specific binding versus time data are fit to a one-site specific binding model, and the B_{max} and K_d for the allosteric molecule are calculated for each orthosteric ligand^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Croy CH, et al. Characterization of the novel positive allosteric modulator, LY2119620, at the muscarinic M(2) and M(4) receptors. Mol Pharmacol. 2014 Jul;86(1):106-15.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA